← Back to Clinical Trials
Recruiting NCT07536841

NCT07536841 Validation of the Odesa Criteria 2026 for Autoimmune Pancreatitis

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07536841
Status Recruiting
Phase
Sponsor Military Medical Clinical Center of the Southern Region, Ukraine
Condition Autoimmune Pancreatitis
Study Type OBSERVATIONAL
Enrollment 82 participants
Start Date 2026-05-01
Primary Completion 2026-05-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
No intervention (observational study)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 82 participants in total. It began in 2026-05-01 with a primary completion date of 2026-05-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This ambispective observational study aims to validate the Odesa Criteria 2026 (OC26), a flexible domain-based point scoring system for diagnosing autoimmune pancreatitis. The study evaluates diagnostic accuracy and reproducibility of OC26 across clinical, serological, morphological, and histological domains.

Eligibility Criteria

Inclusion Criteria: * Adults (≥18 years) undergoing evaluation for suspected autoimmune pancreatitis. * Availability of clinical, serological, imaging, and/or histological data required for OC26 scoring. * Ability to provide informed consent (for prospective participants). Exclusion Criteria: * Confirmed alternative diagnosis explaining pancreatic findings (e.g., pancreatic cancer, acute pancreatitis of other etiology). * Incomplete diagnostic data preventing OC26 scoring. * Prior pancreatic surgery altering diagnostic interpretation.

Contact & Investigator

Central Contact

Oleg Dovbenko, MD, PhD

✉ dovbenko2015@hotmail.com

📞 +380682539685

Principal Investigator

Oleg Dovbenko

PRINCIPAL INVESTIGATOR

Odesa Regional Clinical Medical Center

Frequently Asked Questions

Who can join the NCT07536841 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Autoimmune Pancreatitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07536841 currently recruiting?

Yes, NCT07536841 is actively recruiting participants. Contact the research team at dovbenko2015@hotmail.com for enrollment information.

Where is the NCT07536841 trial being conducted?

This trial is being conducted at Odesa, Ukraine, Odesa, Ukraine.

Who is sponsoring the NCT07536841 clinical trial?

NCT07536841 is sponsored by Military Medical Clinical Center of the Southern Region, Ukraine. The principal investigator is Oleg Dovbenko at Odesa Regional Clinical Medical Center. The trial plans to enroll 82 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology